Ionis Pharmaceuticals (IONS)
In a report issued on January 29, Myles Minter from William Blair maintained a Hold rating on Ionis Pharmaceuticals. The company’s shares closed last Monday at $59.17.
According to TipRanks.com, Minter is ranked #271 out of 5866 analysts.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Ionis Pharmaceuticals with a $70.75 average price target.
Autolus Therapeutics (AUTL)
William Blair analyst Matt Phipps maintained a Buy rating on Autolus Therapeutics today. The company’s shares closed last Monday at $10.05, close to its 52-week low of $9.40.
According to TipRanks.com, Phipps has 0 stars on 0-5 star ranking scale with an average return of -17.3% and a 30.0% success rate. Phipps covers the Healthcare sector, focusing on stocks such as Phasebio Pharmaceuticals, Pieris Pharmaceuticals, and Kezar Life Sciences.
Autolus Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $25.00, a 150.0% upside from current levels. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $24.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.